

Scientific Program

BIOCHEMISTRY/MOLECULAR ONCOLOGY

Room A, 09:00-11:00

Thursday, October 15

Chair Persons: L. Cocco, U. Stein, Y. Zhang

244. Nuclear phospholipase C β 1, high-risk MDS and role of demethylation on its promoter activity. **L. Cocco**, M.Y. Follo, F.A. Manzoli (Bologna, Italy) (25')
233. MACC1 - A key regulator of HGF/Met signaling predicts colon cancer metastasis. **U. Stein**, W. Walther, F. Arlt, H. Schwabe, I. Fichtner, W. Birchmeier, P.M. Schlag (Berlin, Germany) (25')
243. Molecular and cellular control of the membrane-bound Nrf1 transcription factor. **Y. Zhang**, J.D. Hayes (Dundee, UK) (25')
373. A proteomic approach to study anti-proliferative mechanisms of novel derivative of *N*-amidino-substituted benzimidazo [1,2-*a*] quinoline in human colon cancer cells. **M. Sedic**, M. Poznic, P. Gehrig, M. Scott, R. Schlapbach, M. Hranjec, G. Karminski-Zamola, K. Pavelic, S. Kraljevic Pavelic (Zagreb; Rijeka, Croatia; Zurich, Switzerland) (25')
109. Pds5A/SCC-112 - A cell cycle regulatory protein is upregulated in human malignant gliomas. **C. Hagemann**, S. Schommer, B. Weigelin, M. Schulze, R. Patel, K. Roosen, G.H. Vince (Würzburg, Germany; Leicester, UK) (20')

SIGNAL TRANSDUCTION

Room A, 11:30-13:00

Thursday, October 15

Chair Persons: J.A. McCubrey, N.D. Perkins

147. Drug resistance, signaling pathways: roles for in cancer stem cells? **J.A. McCubrey**, W.H. Chappell, S. Abrams, M. Le Hair, R. Franklin, A.M. Martelli, F. Stivala, F. Nicoletti, M. Libra, M. Cervello, L.S. Steelman (Greenville, NC, USA; Bologna; Catania; Palermo, Italy) (30')
169. Regulation of cancer cell proliferation and survival by NF- κ B. **N.D. Perkins** (Bristol, UK) (30')
150. A novel type II inhibitor targeting Plk1. S. Keppner, E. Proschak, G. Schneider, **B. Spänkuch** (Frankfurt am Main, Germany) (20')
187. Studies on potential Wnt/ β -catenin - Target genes in the Notch signalling pathway with special emphasis on colorectal cancer. **J. Ungerbäck**, N. Elander, J. Grünberg, M. Sigvardsson, P. Söderkvist (Linköping, Sweden) (20')

PHARMACOLOGY/CANCER BIOLOGY

Room A, 16:00-17:30
Thursday, October 15

Chair Persons: G. Perletti, M.A. Shamma, P.-H. Chu

274. The pharmacogenetics of aminoglycoside-induced ototoxicity. **G. Perletti**, M. Ferrari, M. Cosentino, E. Marras, V. Magri (Busto Arsizio; Varese; Milano, Italy) (30')
206. Molecular mechanisms underlying genomic instability and the development of drug resistance in cancer. **M.A. Shamma** (Boston, MA, USA) (30')
106. The molecular biomarkers for the intracardiac metastasis from hepatoma. **P.-H. Chu** (Taipei, Taiwan, R.O.C.) (30')

MOLECULAR BIOLOGY/MOLECULAR ONCOLOGY

Room A, 18:00-19:30
Thursday, October 15

Chair Persons: N. Almog, S. Levanat, T. Zhang

328. Molecular signature and regulators of human tumor dormancy. **N. Almog**, L. Ma, L. Hlatky, J. Folkman, A. Abdollahi (Boston, MA, USA) (30')
120. Hedgehog-Gli signaling pathway interactions and therapeutic potential in proliferative tumors of the ovary. **S. Levanat**, M. Cretnik, V. Musani, P. Ozretic, S. Oreskovic (Zagreb, Croatia) (30')
121. Multi-signaling pathway-mediated cleavage of the cytoplasmic domain of hepaCAM, a process that alters the functions of hepaCAM in the human breast carcinoma MCF7 cells. **T. Zhang**, M.C. Moh, L.H. Lee, S. Shen (Singapore) (30')

EXPERIMENTAL ONCOLOGY/PHARMACOLOGY

Room B, 09:00-11:00
Thursday, October 15

Chair Persons: M. Reinis, N. Latruffe

351. Modulation of anti-tumour immunity and immune suppression by epigenetic agents. **M. Reinis**, I. Stepanek, J. Simova, M. Indrova, S. Moravcova, H. Pribylova, T. Hejhal, J. Manning, J. Bubenik (Prague, Czech Republic) (25')
352. Induction of effective immune responses against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines. **M. Reinis**, I. Stepanek, J. Simova, J. Bieblova, H. Pribylova, M. Indrova, J. Bubenik (Prague, Czech Republic) (25')
101. New perspectives open by resveratrol analogues in the inhibition of human colorectal tumor cell proliferation. F. Mazué, D. Colin, J. Gobbo, M. Wegner, C. Spatafora, D. Fasseur, D. Delmas, P. Meunier, C. Tringali, **N. Latruffe** (Dijon, France; Catania, Italy) (25')
367. How do cancer stem cells maintain unlimited lifespan? **T. Simonsson** (Gothenburg, Sweden) (25')
240. KRAS mutation status in primary colorectal cancer and in matched metastases. **W. Dietmaier**, A. Kiesl, C. Vogel, B. Groesch, P. Ruummele, F. Hofstaedter (Regensburg, Germany) (20')

CLINICAL ONCOLOGY/MOLECULAR ONCOLOGY

Room B, 11:30-13:00
Thursday, October 15

Chair Persons: A. Sedo, A. Vral

365. Molecules with dipeptidyl peptidase-IV enzymatic activity and growth properties of human glioblastoma cells. **A. Sedo**, P. Busek, J. Stremenova, L. Sromova, E. Krepela (Prague, Czech Republic) (20')
275. The radiosensitizing effect of Ku70-80 knockdown by RNA interference in the MCF10A breast epithelial cell line irradiated with low LET X-rays and high LET radiotherapy neutrons. V. Vandersickel, M. Mancini, J.P. Slabbert, E. Marras, H. Thierens, G. Perletti, **A. Vral** (Gent, Belgium; Varese, Italy; Somerset West, South Africa) (20')
208. RNASET2, a human tumor antagonizing gene suppressing tumor growth *in vivo* but not *in vitro*. **F. Acquati**, L. Monti, S. Bertilaccio, P. Campomenosi, A. Grimaldi, P. Bonetti, P. Ghia, F. Sanvito, C. Doglioni, C. Riva, C. Capella, R. Taramelli (Varese; Milano, Italy) (20')
136. Cross-talk between interferon alpha-2b and TGFbeta₁ signaling pathways in preneoplastic liver. **M.C. Carrillo** (Rosario, Argentina) (15')
393. Pancreatic cancer and cholangiocarcinoma - New therapeutic options *in vivo* and *in vitro* by new synthetic MMP-I. **A. Pries**, H. Tschesche, H.-P. Bruch, M.-L. Kruse, M. Kapischke (Hamburg, Germany) (15')

PHARMACOLOGY/BIOCHEMISTRY/IMMUNOLOGY

Room B, 16:00-17:30
Thursday, October 15

Chair Persons: R. Donev, B. Eiz-Vesper

142. Interplay between REST and nucleolin transcription factors is a key mechanism in regulation of expression of immunomodulatory and cell survival genes; implications for cancer immunotherapy. M. Kolev, T. Tediose, P. Brennan, B.P. Morgan, **R. Donev** (Cardiff, UK) (25')
271. Heat shock protein 70 induces cytotoxicity of T-helper cells and augmented the immunosuppressive capacity of FoxP3⁺ T regulatory cells. **B. Eiz-Vesper**, C. Figueiredo, J. Wachstein, A. Bajor, R. Dressel, M. Wittmann, R. Blasczyk (Hannover; Goettingen, Germany; Leeds, UK) (25')
183. Correlation between immunological findings and *in vivo* microscopy can assist evaluation of treatment effectiveness in mouse melanoma hyperthermia. **L. Vannucci**, V. Grobarova, J. Strnadel, O. Chernyavskiy, P. Togni, J. Klepetar, L. Kubinova, J. Vrba, P. Rossmann, A. Fiserova (Prague, Czech Republic) (20')
146. Mechanisms underlying chemotherapy and subsequent immunotherapy with IL-12-producing cellular vaccines in a murine model of HPV 16-associated tumours. **M. Indrová**, J. Bieblová, J. Rossowska, E. Pajtasz-Piasecka, J. Bubeník, M. Reinis (Prague, Czech Republic; Wroclaw, Poland) (20')

APOPTOSIS/MOLECULAR ONCOLOGY

Room B, 18:00-19:30
Thursday, October 15

Chair Persons: M.R. Faraone Mennella, U. Armato

116. Poly(ADP-ribose) polymerase as a tool for detecting apoptosis: Diagnostic and therapeutic perspectives. A. De Maio, E. Natale, E. Porzio, C. Mistretta, **M.R. Faraone Mennella** (Naples, Italy) (25')
229. Nuclear and cytoplasmic mechanisms of apoptosis triggered by photoactivated Calphostin C in neoplastic cells. A. Chiarini, **U. Armato**, M. Marconi, J.F. Whifield, I. Dal Pra (Verona, Italy; Ottawa, Canada) (25')
122. Expression pattern of the apoptosis-related genes (p53, PUMA, BAX, and C-MYC) and their impact on outcome in early stage (FIGO I-II) serous papillary ovarian carcinoma. **I. Skírnisdóttir**, B. Sorbe, T. Seidal (Uppsala; Örebro; Halmstad, Sweden) (20')
322. Growth suppression and apoptosis induction in human hepatoma cells by DHMEQ. A novel NF- κ B inhibitor, is mediated through a ROS-dependent mechanism. N. Lampiasi, A. Azzolina, N. D'Alessandro, K. Umezawa, J.A. McCubrey, G. Montalto, **M. Cervello** (Palermo, Italy; Kanagawa, Japan; Greenville NC, USA) (20')

VIRUSES/PATHOGENESIS

Room C, 09:00-11:00
Thursday, October 15

Chair Persons: M. El-Salhy, K. Umezawa

376. Low density of ghrelin cells in the oxyntic mucosa correlated to slow gastric emptying in patients with diabetes type 1. **M. El-Salhy**, J. Rauma (Bergen; Stord, Norway) (25')
104. *In vitro* and *in vivo* anti-neoplastic activity of the specific NF-kappa B inhibitor DHMEQ on AIDS-related lymphoma. **K. Umezawa**, Y. Kan-bayashi, A. Miyake, T. Watanabe, R. Horie (Yokohama; Tokyo; Kanagawa, Japan) (25')
144. Lymphoproliferative disorders in Germany: Strong association with SV40 and coalteration of p53. **S. Heinsohn**, R. Scholz, H. Kabisch (Hamburg, Germany) (25')
178. Glucose-regulated protein 78 is an intracellular antiviral factor against hepatitis B virus. **Y. Ma**, H. Wang, Y. Chen, S.-N. Tsai, S.-M. Ngai, H.-F. Kung, C.H.K. Cheng, M.-L. He (Hong Kong, P.R. China) (25')
105. Discovery of a novel AP-1 function inhibitor DTCM-glutarimide derived from an antibiotic 9-methylstreptimidone. **M. Tachibana**, Y. Ishikawa, S. Nishiyama, K. Umezawa (Yokohama, Japan) (20')

BRAIN TUMORS/MOLECULAR ONCOLOGY

Room C, 11:30-13:00
Thursday, October 15

Chair Persons: M. Jhanwar-Uniyal, R. Abounader

305. mTOR signaling pathways in tumorigenesis of glioblastoma multiforme: Involvement of cancer stem cells. **M. Jhanwar-Uniyal** (Valhalla, NY, USA) (25')
331. c-Met pathway in brain tumors. F. Guessous, Y. Zhang, Y. Li, C. Di Pierro, A. Kofman, D. Schiff, **R. Abounader** (Charlottesville, VA, USA) (25')
168. The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat. **M.-L. He** (Hong Kong, P.R. China) (20')
175. Evaluation of mammalian thioredoxin reductase/thioredoxin as a direct link between EGCG targets and effects on cellular redox status. H. Zhang, D. Cao, X. Qian, **L. Zhong** (Beijing, P.R. China) (20')

RADIOLOGY/RADIOTHERAPY/VACCINE

Room C, 16:00-17:30
Thursday, October 15

Chair Persons: A. Spanu, C.J. Xian, Y.-J. Lee

180. Pathobiology and prevention of bone growth defects caused by cancer chemotherapy. **C.J. Xian**, C.M. Fan, J.C. Cool, M.A. Scherer, T. King, K.R. Georgiou, R.R. Nadhanan, G.S. Howarth, T. Shandala, B.K. Foster (Adelaide, Australia) (25')
198. Multi-modality imaging of the effects of actin depolymerizing factor (ADF)/cofilin on tumorigenesis using a small animal model. C.-H. Tsai, J.J. Hwang, H.E. Wang, R.S. Liu, **Y.-J. Lee** (Taipei, Taiwan, R.O.C.) (25')
262. Radioisotopic molecular imaging in breast cancer. **A. Spanu**, G. Madeddu (Sassari, Italy) (20')
179. Genomic alterations in rectal tumors and response to neo-adjuvant radio-chemotherapy. **D. Calistri**, C. Molinari, M. Ballardini, N. Teodorani, M. Giannini, W. Zoli, E. Emiliani, E. Lucci, L. Saragoni, R. Silvestrini, D. Amadori (Meldola; Ravenna; Forli, Italy) (20')

MOLECULAR ONCOLOGY/DIAGNOSIS/IMMUNOLOGY

Room C, 18:00-19:30
Thursday, October 15

Chair Persons: H. Kosmehl, R. Vento

140. Matrix protein supported oral brush biopsy - A novel method to identify oral cancer and its precursors. **H. Kosmehl**, R. Dahse, O. Driemel (Erfurt; Lüneburg, Germany) (25')
186. 3AB-OS, a new human pluripotent cancer stem cell: Properties and expectations for practical applications. R. Di Fiore, A. Santulli, P. Di Fazio, R. Drago-Ferrante, M. Ocker, G. Tesoriere, **R. Vento** (Palermo; Trapani, Italy) (25')
273. Unconventional function of the polycomb group proteins in differentiated T helper cells. H. Reut, J. Eyal, O.L. Ben-Mordechai, Y. Boyko, **O. Avni** (Haifa, Israel) (20')
291. NFAT family of transcription factors in tumor development. B.K. Robbs, A.L.S. Cruz, G.P. Mognol, **J.P.B. Viola** (Rio de Janeiro, Brazil) (20')

MOLECULAR MEDICINE

Room D, 09:00-11:00
Thursday, October 15

Chair Persons: K. Ohlendieck, C. Sato, C. Gragnoli

227. Electron microscopy as a tool for determining protein 3D structure related to channel diseases and metastasis. K. Mio, T. Ogura, Y. Maruyama, **C. Sato** (Ibaraki, Japan) (20')
108. Biochemical and proteomic profiling of diabetic skeletal muscle. E. Mullen, **K. Ohlendieck** (Kildare, Ireland) (20')
388. *PSMD9* gene in linkage with type 2 diabetes in Italians in the NIDDM2 locus. **C. Gragnoli** (Hershey, PA; Philadelphia, PA, USA; Rome, Italy) (20')
174. Rhodamine 123 efflux in human subpopulations of haematopoietic stem cells: Comparison between bone marrow, umbilical cord blood and mobilized peripheral blood CD34⁺ cells. **K. Wagner-Souza**, H.R. Diamond, M.H. Ornellas, B.E. Gomes, A. Almeida-Oliveira, E. Abdelhay, L.F. Bouzas, V.M. Rumjanek (Rio de Janeiro, Brazil) (20')
196. GABA and its GABA_A receptor are expressed in psoriasis and may have a role in pruritus. R. Nigam, B. Amatya, H. El-Nour, **K. Nordlind** (Stockholm, Sweden) (20')
323. Biological effects of high energy shock waves on cord blood CD34⁺ cells. **F. Timeus**, R. Frairia, N. Crescenzo, S. Pillozzi, M.O. Mereuta, F. Sanavio, A. Doria, L. Foglia, S. Pagliano, E. Cilia, A. Masi, M. Berger, L. Cordero di Montezemolo, A. Arcangeli, F. Fagioli (Turin; Florence, Italy) (20')

MOLECULAR MEDICINE

Room D, 11:30-13:00
Thursday, October 15

Chair Persons: Y. Suzuki, N. Jahroudi

189. L-type calcium channels: A new player in the regulation of immune cell function and survival. **Y. Suzuki**, T. Inoue, M. Murai, K. Hayama, T. Yoshimaru, C. Ra (Tokyo; Tokushima, Japan) (25')
222. Transacting factors that regulate gene expression specifically in lung endothelial cells. **N. Jahroudi** (Edmonton, Canada) (25')
255. Biomarkers in multiple sclerosis evaluated in Brazilian patients - I: CCR5 and HLA-DRB1* genetic polymorphisms. D.R. Kaimen-Maciel, **E.M.V. Reiche**, S.D. Borelli, H.K. Morimoto, M.A.E. Watanabe, F.C. Melo, J. Lopes, E.M. Yamaguchi, T.L. Silveira, W.V. Da Silva Júnior, E.R. Comini-Frota, T. Matsuo (Londrina; Maringá; Belo Horizonte, Brazil) (20')
256. Biomarkers in multiple sclerosis evaluated in Brazilian patients - II: Specific IgG antibodies against Epstein-Barr virus antigens. D.R. Kaimen-Maciel, **E.M.V. Reiche**, H.K. Morimoto, J. Lopes, E.M. Yamaguchi, T.L. Silveira, G.B. Peraro, N. Wysocki, M.M. De Souza, T. Matsuo (Londrina, Brazil) (20')

MOLECULAR MEDICINE

Room D, 16:00-17:30
Thursday, October 15

Chair Persons: R. Gambari, K. Mio

- 341. Micro RNAs, erythroid differentiation and fetal hemoglobin induction. **R. Gambari** (Ferrara, Italy) (30')
- 310. Single particle analysis of ion channels and the sensor molecules. **K. Mio**, T. Ogura, Y. Maruyama, M. Mio, C. Sato (Tokyo, Japan) (30')
- 300. Molecular aspects of cardiovascular disease. **B. Süsleyici Duman** (Göztepe, Turkey) (30')

MOLECULAR MEDICINE/MOLECULAR ONCOLOGY

Room D, 18:00-19:30
Thursday, October 15

Chair Persons: V. Lalioti, P.A. Lazo

- 361. The atypical kinase Cdk5 is activated by insulin, regulates the association between GLUT4 and E-Syt1, and modulates glucose transport in 3T3-L1 adipocytes. **V. Lalioti**, G. Muruais, A. Dinarina, J. van Damme, J. Vandekerckhove, I.V. Sandoval (Madrid, Spain; Ghent, Belgium) (30')
- 224. Autoregulatory loop between VRK1 and p53 mediated by DRAM in response to DNA damage in human cells. **P.A. Lazo**, A. Valbuena, S. Castro-Obregón (Salamanca, Spain; Morelos, México) (30')
- 326. The role of glycosylation in the interaction of tumor and immune cells. **V. Benson**, V. Grobárová, J. Richter, A. Fiserová (Prague, Czech Republic) (30')

MOLECULAR MEDICINE

Room E, 09:00-11:00
Thursday, October 15

Chair Persons: I. Di Liegro, T. Takahashi

296. Shedding of extracellular membrane vesicles from brain cells in culture. G. Schiera, P. Proia, A. Lo Cicero, P. Saladino, G. Savettieri, **I. Di Liegro** (Palermo, Italy) (30')
151. Protective role of heme oxygenase-1 in intestinal tissue injury and inflammation. **T. Takahashi** (Okayama, Japan) (30')
132. Factors ruling granulocytic differentiation: What could we learn from congenital disorders of hematopoiesis? **J. Skokowa**, K. Welte (Hannover, Germany) (30')
153. Adipokines and asymmetric dimethylarginine in l-carnitine supplemented patients with end-stage renal disease on regular hemodialysis. **E. Sulyok**, B. Csiky, M. Rauch, W. Rascher, J. Martens-Lobenhoffer, S.M. Bode-Böger (Pécs, Hungary; Erlangen-Nürnberg; Magdeburg, Germany) (15')
164. Interdependence of laminin-mediated clustering of lipid rafts and the dystrophin complex in astrocytes. G. Noël, D.K.L. Tham, **H. Moukhles** (Vancouver, Canada) (15')

MOLECULAR MEDICINE

Room E, 11:30-13:00
Thursday, October 15

Chair Persons: W.J. Malaisse, J.M. Jones

154. Comparison between liver and brain alterations of phospholipid ω 3 and ω 6 fatty acid content in ω 3-depleted rats. **W.J. Malaisse**, M. Hacquebard, L. Portois, Y.A. Carpentier (Brussels, Belgium) (25')
156. Potential role for KPNA1 in regulation of V(D)J recombination. **J.M. Jones** (Washington DC, USA) (25')
403. Macrophage migration inhibitory factor as potential therapeutic target for prevention and treatment of autoimmune diabetogenesis. Lessons from animal models. **F. Nicoletti**, S. Stosic-Grujicic (Catania, Italy; Belgrade, Serbia) (20')
117. Carbon monoxide inhalation therapy reduces dyspnea through decrease in pulmonary artery pressure in patients with chronic obstructive pulmonary disease with secondary pulmonary hypertension. **H. Yasuda**, T. Sasaki, K. Nakayama, M. Yamaya (Sendai, Japan) (20')

MOLECULAR ONCOLOGY (CYTOGENETICS)

Room E, 16:00-17:30
Thursday, October 15

Chair Persons: K. Smetana Jr, I.A. Prior

166. Molecular properties of stromal fibroblasts from the squamous cell carcinoma of the head and neck. **K. Smetana Jr**, B. Dvoránková, L. Lacina, M. Kolár, H. Strnad, C. Vlcek (Prague, Czech Republic) (30')
190. Phosphatases negatively regulating oncogenic Ras signaling. J. Omerovic, M.J. Clague, **I.A. Prior** (Liverpool, UK) (30')
201. Chromosomal damage determined in peripheral blood lymphocytes of cancer patients and healthy individuals. Z. Polívková, S. Sytarová, L. Vodicková, H. Demová, A. Naccarati, V. Poláková, M. Ambrus, M. Cerná, **P. Vodicka** (Prague, Czech Republic) (30')

MOLECULAR MEDICINE/MOLECULAR ONCOLOGY

Room E, 18:00-19:30
Thursday, October 15

Chair Persons: P. Vodicka, A. Mohr

202. Tracking sporadic colorectal cancer susceptibility: Functional studies on DNA repair. **P. Vodicka**, J. Slysková, M. Hánová, M. Hubácková, L. Vodicková, L. Lipská, A. Naccarati, P. Soucek (Prague, Czech Republic) (25')
325. Manganese superoxide-dismutase inhibits TRAIL-induced apoptosis by blocking the release of pro-apoptotic factors from mitochondria. **A. Mohr**, C. Buenecker, R. Gough, R. Zwacka (Galway, Ireland) (25')
327. Anti-tumor promoting potential of curcumin. **M. Iqbal** (Kota Kinabalu, Malaysia) (20')
396. Effect of FADD expression during UV carcinogenesis. M. Radnic, I. Matic, **B. Nagy** (Zagreb, Croatia) (20')

EXPERIMENTAL THERAPEUTICS

Room A, 09:00-11:00
Friday, October 16

Chair Persons: H. Modjtahedi, O.-G. Issinger, W. Walther

217. EGFR targeting in cancer: Advances and challenges. **H. Modjtahedi**, M.P. Cunningham, S.A. Khelwatty, R. Kirk, S. Eccles (Kingston; Guildford; Sutton, UK) (30')
137. Protein kinase CK2: An old kinase as a novel drug target. I.S. Sandholt, J. Raaf, B.B. Olsen, B. Guerra, K. Niefind, **O.-G. Issinger** (Odense, Denmark; Cologne, Germany) (30')
236. Nonviral gene transfer for treatment of cancer. **W. Walther**, D. Kobelt, R. Siegel, J. Aumann, U. Stein, P.M. Schlag (Berlin, Germany) (30')
269. Development of new drugs for the treatment of ER-negative breast cancer: Success with novel curcumin-based compounds. S. Taurin, B. Yadav, K. Allen, T.J. Somers-Edgar, L. Larsen, **R.J. Rosengren** (Dunedin, New Zealand) (30')

EXPERIMENTAL THERAPEUTICS

Room A, 11:30-13:00
Friday, October 16

Chair Persons: U. Mahlknecht, W. El-Rifai

280. Emerging epigenetic treatment strategies in oncology. **U. Mahlknecht** (Homburg/Saar, Germany) (20')
281. Influence of environmental factors on epigenetic regulation. **U. Mahlknecht** (Homburg/Saar, Germany) (20')
339. From integrated genomics to therapeutics in cancer: The 20q amplicon. **W. El-Rifai** (Nashville, TN, USA) (25')
409. Organ preservation strategies in bladder cancer and the results of BC2001 trial, a Phase III trial of chemoradiotherapy in muscle invasive bladder cancer. **S.A. Hussain**, N.D. James (Birmingham, UK) (25')

EXPERIMENTAL THERAPEUTICS

Room A, 15:00-16:30
Friday, October 16

Chair Persons: B. Rigas, B. Bonavida

311. A molecular cross-talk cell signaling circuitry regulates tumor resistance and metastasis: Identification of novel therapeutic small molecules that reverse these phenotypes. **B. Bonavida**, K. Yeung, S. Baritaki (Los Angeles, CA; Toledo, OH, USA) (25')
119. Phospho-valproic acid (MDC-118): A novel anticancer agent. G. Mackenzie, L. Huang, R. Gupta, F. Johnson, **B. Rigas** (Stony Brook, NY, USA) (25')
282. Chemokine receptors in cancer: Attractive but complex drug targets. **N. Heveker** (Montréal, Canada) (25')
394. The redox-dependent growth inhibitory effect of phosphoaspirin (MDC-43) on human cancer cell lines. W. Zhao, G. Mackenzie, **O. Murray**, Z. Zhang, B. Rigas (Stony Brook, NY, USA) (15')

MOLECULAR ONCOLOGY/TUMOR BIOLOGY

Room A, 17:00-18:30
Friday, October 16

Chair Persons: P.E. Nielsen, C. Hu

383. Cell penetrating peptides as delivery vehicles for RNA interference agents *ex vivo* and *in vivo*. Towards dissecting uptake mechanisms. **P.E. Nielsen**, T. Shiraishi (Copenhagen, Denmark) (30')
139. Integrin trafficking in migration of cancer cells: Role of SNARE proteins. N. Hasan, K.A. Riggs, K. Luftman, P. Day, D. Hardee, **C. Hu** (Louisville, KY, USA) (30')
170. Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma. B. Keenen, H. Qi, S.V. Saladi, M. Yeung, **I.L. De la Serna** (Toledo, OH, USA) (30')

APOPTOSIS/THERAPEUTICS

Room B, 09:00-11:00
Friday, October 16

Chair Persons: S. Emanuele, S. Katzav, F. Stivala

337. Parthenolide sensitizes human hepatocarcinoma cells to TRAIL-induced apoptosis. **S. Emanuele**, A. D'Anneo, D. Carlisi, M. Lauricella, L. Angileri, A. Ciruolo, R. Montalbano, R. Vento, G. Tesoriere (Palermo, Italy) (25')
195. Mechanism of Vav1-mediated cancer cell growth: Is it a new target in human cancer? G. Lazer, Y. Idelchuk, V. Schapira, E. Pikarsky, **S. Katzav** (Jerusalem, Israel) (25')
353. Dietary fatty acids modulate the effects of TNF family apoptotic inducers. **J. Hofmanová**, A. Vaculová, M. Hyzd'alová, L. Kocí, B. Skender, A. Kozubík (Brno, Czech Republic) (25')
384. Prognostic significance of YY1 in high grade lymphomas. **M. Libra**, S. Canevari, G. Malaponte, M.C. Mazzarino, F. Nicoletti, S. Travali, J.A. McCubrey, B. Bonavida, F. Stivala (Catania; Milan, Italy; Greenville, NC; Los Angeles, CA, USA) (25')
270. The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide. I.-C. Lien, S.-C. Mei, L.-Y. Horng, **R.-T. Wu** (Taipei, Taiwan, R.O.C.) (20')

CANCER THERAPEUTICS/SIGNALING

Room B, 11:30-13:00
Friday, October 16

Chair Persons: P. Fishman, N.S. Duesbery, V. Bravou

102. Utilization of the A₃ adenosine receptor to treat hepatocellular carcinoma (HCC): From bench to bedside. **P. Fishman**, S.M. Stemmer, A. Ochaion, S. Cohn, R. Patoka, F. Barer, S. Bar-Yehuda (Petach-Tikva, Israel) (25')
395. MKK signaling in tumor growth and angiogenesis. **N.S. Duesbery** (Grand Rapids, MI, USA) (25')
161. Integrin-linked-kinase: New insights in signaling and cancer. **V. Bravou** (Patras, Greece) (20')
163. Caveolin-1 and galectin-3: Plasma membrane domain effectors of tumor cell signaling and migration. S. Strugnell, B. Joshi, **I.R. Nabi** (Vancouver, Canada) (20')

BIOCHEMISTRY/MOLECULAR ONCOLOGY

Room B, 15:00-16:30
Friday, October 16

Chair Persons: G. Sica, E. Agostinelli

194. Cell spreading and neoangiogenesis in glioblastoma multiforme and in peritumor tissue. **G. Sica**, G. Lama, C. Spanò, G. Proietti, A. Mangiola, C. Anile, L. Lauriola, G. Maira, M. Jhanwar-Uniyal (Rome, Italy; Valhalla, NY, USA) (30')
364. MDL 72527 and chloroquine potentiate cell death induced by enzymatic oxidation products of spermine on human cancer cells. **E. Agostinelli**, M. Condello, A. Molinari, G. Tempera, S. Saccoccio, N. Viceconte, G. Arancia (Rome, Italy) (30')
385. Factors and cofactors of cervical cancer development. **A. Gozdicka-Józefiak**, J. Broniarczyk, M. Kaczorowska, A. Warowicka, J. Pacholska-Bogajska, A. Józefiak, A. Kwasniewska, W. Kedzia (Poznan; Lublin, Poland) (30')

CLINICAL ONCOLOGY/MOLECULAR ONCOLOGY

Room B, 17:00-18:30
Friday, October 16

Chair Persons: W.A. Yeudall, D. Steinbach

338. EPS8 in oncogenesis. H. Wang, V. Patel, H. Miyazaki, J.S. Gutkind, **W.A. Yeudall** (Richmond, VA; Bethesda, MD, USA) (25')
329. Prenatal origin of childhood acute lymphoblastic leukemia, in children of all age groups. B. Gruhn, J.W. Taub, Y. Ge, J.F. Beck, R. Zell, R. Häfer, F.H. Hermann, K.-M. Debatin, **D. Steinbach** (Jena; Greifswald; Ulm, Germany; Detroit, MI, USA) (25')
251. The antineoplastic properties of a novel class of NSAID-based compounds: Significantly enhanced potency compared to their parent compounds. **L. Huang**, Y. Sun, G. Mackenzie, R. Gupta, F. Johnson, B. Rigas (Stony Brook, NY, USA) (20')
340. Role of CDK6 in T cell development and tumorigenesis. **M.G. Hu**, A. Deshpande, N. Schlichting, E.A. Hinds, C. Mao, M. Dose, G.-F. Hu, F. Gounari, P.W. Hinds (Boston, MA, USA) (20')

POSTERS
WINE TASTING

POSTER VIEWING 18:30-19:30
Friday, October 16

MOLECULAR ONCOLOGY/PHARMACOLOGY

Room C, 09:00-11:00
Friday, October 16

Chair Persons: L.M. Khachigian, G. Markel, C. Thuwajit

391. Immediate-early genes as master regulators in cancer and other vascular disease. **L.M. Khachigian** (Sydney, Australia) (30')
390. The role of CEACAM1 in metastatic melanoma and therapeutic implications. R. Ortenberg, S. Sapoznik, M. Besser, A. Treves, A. Orenstein, J. Schachter, **G. Markel** (Ramat-Gan, Israel) (25')
211. Role of tumor-associated fibroblast in the promotion and progression of cholangiocarcinoma. **C. Thuwajit**, K. Utispan, P. Thuwajit, Y. Abiko, K. Charngkaew, A. Paupairoj, S. Chau-in (Bangkok; Khon Kaen, Thailand; Matsudo, Japan) (20')
213. Isolation and characterization of CSC from human glioma cell lines. **F. Iacopino**, S. Ferracuti, C. Angelucci, G. Sica (Rome, Italy) (15')
258. Anti-tumor effect of novel Snail-p53 binding specific inhibitor in K-Ras mutated cancer cells. S.H. Lee, Y.S. Jung, S.J. Lee, J.Y. Chung, N.C. Ha, G.Y. Song, **B.J. Park** (Busan, Korea) (15')
294. Identification of cancer stem cell antigens revealed unique characteristics of triple negative breast cancer. **T. Torigoe**, Y. Hirohashi, A. Takahashi, H. Asanuma, M. Nakatsugawa, S. Inoda, N. Sato (Sapporo, Japan) (15')

MOLECULAR ONCOLOGY/APOPTOSIS

Room C, 11:30-13:15
Friday, October 16

Chair Persons: A. Orzechowski, T. Eckschlager

172. Sodium butyrate sensitizes COLO 205 cells to both intrinsic and TNF- α -dependent extrinsic apoptosis. **B. Pajak**, B. Gajkowska, A. Orzechowski (Warsaw, Poland) (20')
173. Segregation of pro- and antiapoptotic signals in lipid rafts. S. Orzechowska, B. Pajak, B. Gajkowska, **A. Orzechowski** (Warsaw, Poland) (25')
210. Reovirus induced cell death in hypoxic and apoptosis resistant medulloblastoma cells. K. Figová, J. Hrabeta, **T. Eckschlager** (Prague, Czech Republic) (25')
260. Apoptosis induced by valproic acid under normoxic and hypoxic conditions in neuroblastoma cell lines. **S. Cipro**, J. Hrebacková, J. Hrabeta, J. Poljaková, T. Eckschlager (Prague, Czech Republic) (20')
261. Expression profile in DNA repair genes in patients with early stages of laryngeal cancer. **L. Vodickova**, R. Vaclavikova, M. Hanova, I. Hlavata, M. Ehrlichová, D. Kovar, P. Soucek, P. Vodicka (Prague, Czech Republic) (15')

BREAST CANCER

Room C, 15:00-16:30
Friday, October 16

Chair Persons: N. Telang, F. Behbod, J.M. Flanagan

149. Breast and colon cell lines from genetically engineered mice: Novel *in vitro* models for carcinogenesis and cancer prevention. **N. Telang**, M. Katdare (Montvale, NJ; New York, NY, USA) (20')
123. An intra-ductal human-in-mouse (HIM) transplantation model mimics the subtypes of ductal carcinoma *in situ*. **F. Behbod**, F.S. Kittrell, H. La Marca, D. Edwards, S. Kerbawy, J.C. Heestand, E. Young, P. Mukhopadhyay, H.-W. Yeh, D.C. Allred, M. Hu, K. Polyak, J.M. Rosen, D. Medina (Kansas City, KS; Houston, TX; St. Louis, MO; Boston, MA, USA) (20')
408. Epigenetic variation in repetitive elements as a risk factor for breast cancer. **J.M. Flanagan** (London, UK) (20')
113. A key role of NF- κ B pathways in breast cancer stem cells for tumorigenesis. M. Murohashi, T. Isagawa, S. Tsuji, K. Umezawa, H. Aburatani, **N. Gotoh** (Tokyo, Japan) (15')
185. Gefitinib, lapatinib and sorafenib alter cytosolic calcium concentration and xenobiotic extrusion activity in breast cancer cells. **F. Fabbri**, S. Carloni, G. Brigliadori, E. Bandini, P. Ulivi, R. Silvestrini, D. Amadori, W. Zoli (Meldola, Italy) (15')

BREAST CANCER

Room C, 17:00-18:30
Friday, October 16

Chair Persons: M.A. Nagai, M. Shekhar

264. Regulation of *PAWR* expression by estrogen and growth factors in breast cancer cells. S.A. De Bessa-Garcia, M.C. Pereira, **M.A. Nagai** (São Paulo, Brazil) (25')
160. The postreplication DNA repair enzyme, Rad6, multiple guises in breast carcinogenesis. **M. Shekhar** (Detroit, MI, USA) (25')
193. c-Met/HGF-dependent and -independent functions of Syndecan-1 in breast cancer cell proliferation and invasiveness. S.A. Ibrahim, L. Kiesel, G.W. Yip, **M. Götte** (Münster, Germany; Singapore) (20')
220. Novel function of ERp29 in mesenchymal-epithelial transition in invasive breast cancer cells. S. Xu, I.F. Bambang, **D. Zhang** (Singapore) (20')

MOLECULAR MEDICINE/MOLECULAR ONCOLOGY

Room D, 09:00-11:00
Friday, October 16

Chair Persons: L.J. Fanning, G.W. Yip

197. Quasispecies: Future proofing RNA viruses. **L.J. Fanning** (Cork, Ireland) (25')
225. Investigation of the regulatory roles of heparan sulphation in breast cancer. **G.W. Yip**, C.Y. Koo, P.H. Tan, B.H. Bay (Singapore) (25')
265. Oxidative stress to overcome drug-resistance. **J.K. Kwee**, D.G. Luque, A.C.S. Ferreira, F.C. Vasconcelos, K.L. Silva, C.E. Klumb, R.C. Maia (Rio de Janeiro, Brazil) (25')
360. Hematological malignancies are sensitive to the cytotoxic effect of melatonin. **C. Rodriguez**, S. Casado-Zapico, G. García-Santos, J. Rodriguez-Blanco, V. Martín, F. Herrera, A.M. Sánchez-Sánchez, I. Antolín (Oviedo, Spain) (25')
247. Accuracy of ^{99m}Tc-sestamibi scintimammography in breast cancer diagnosis. **S.M. Moriguchi**, L.A. De Luca, B.L. Griva, K.H. Koga, E. Tinois, H. Vespoli, G. Uemura (São Paulo, Brazil) (20')

COLON CANCER

Room D, 11:30-13:00
Friday, October 16

Chair Persons: N. Perreault, H. Ashktorab

219. Loss of Smad5 disrupts the intestinal epithelial barrier by disassembling the apical junctional complex and increasing susceptibility to experimental colitis. J. Allaire, M. Darsigny, S. Marcoux, A. Zwijsen, F. Boudreau, **N. Perreault** (Sherbrooke, Canada; Leuven, Belgium) (25')
228. Hnf4alpha is up-regulated in colon cancer, limits the production of reactive oxygen species and contributes to intestinal neoplasia. M. Darsigny, J.-P. Babeu, E. Lévy, N. Rivard, J. Carrier, N. Perreault, **F. Boudreau** (Sherbrooke, Canada) (25')
133. The beginning of the end in colorectal cancer: From genome to epigenome. **H. Ashktorab**, H. Brim, E. Lee, D. Smoot (Washington, DC, USA) (20')
158. Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. T. Winder, **A. Mündlein**, S. Geller-Rhomberg, K. Dirschmid, B.L. Hartmann, M. Knauer, H. Drexel, E. Wenzl, A. De Vries, A. Lang (Feldkirch, Austria; Triesen, Principality of Liechtenstein) (20')

MOLECULAR ONCOLOGY

Room D, 15:00-16:30
Friday, October 16

Chair Persons: N. Rivard, A. Semczuk

214. E2F4 is a critical modulator of proliferation and senescence in human intestinal epithelial cells. H. Garneau, M.-C. Paquin, **N. Rivard** (Sherbrooke, Canada) (25')
292. Biogenesis and functions of lipid droplets in inflammation and cancer. **P.T. Bozza**, J.P.B. Viola (Rio de Janeiro, Brazil) (25')
354. The prevalence of allelic loss at *TP53* in metastatic human endometrial cancer. **A. Semczuk**, W. Szewczuk, P. Olcha, K. Postawski, R. Schneider-Stock (Lublin, Poland; Erlangen, Germany) (20')
359. Poly (ADP-ribose) polymerase-1 (PARP-1) activity in normal and cancerous human endometrium. M. Monist, **K. Postawski**, K. Romanek (Lublin, Poland) (20')

MOLECULAR MEDICINE

Room D, 17:00-18:30
Friday, October 16

Chair Persons: E. Yetkin, N.M. Sifakas

284. Molecular and cellular mechanisms of aortic stenosis. **E. Yetkin** (Bolu, Turkey) (30')
379. Differential expression of SDF-CXCR4 biological axis in bone marrow mesenchymal stem cells in rheumatoid arthritis associated lung fibrosis. **K.M. Antoniou**, A. Proklou, R. Lymbouridou, G. Soufla, I. Lasithiotaki, K. Karagiannis, D.A. Spandidos, N.M. Sifakas (Heraklion, Greece) (20')
286. Hyperlipidaemic conditions induce 'metabolic memory' within human abdominal subcutaneous adipose tissue and isolated adipocytes, *in vitro*. **A.L. Harte**, E.M. Youssef, M.S. Abdalla, H.M. Sharada, E. Ashour, A.I. Amin, A. Cerellio, P. O'Hare, S. Kumar, P.G. McTernan (Coventry, UK; Helwan; Giza; Cairo, Egypt) (20')
295. The effect of Baclofen and NNLA treatment on spinal cord spasticity. **N. Lukáčová**, A. Dávidová, L. Capková, I. Vanicky, M. Chalimoniuk, J. Langfort, J. Strosznajder (Kosice, Slovak Republic; Warsaw, Poland) (20')

EXPERIMENTAL THERAPEUTICS

Room A, 09:00-11:00
Saturday, October 17

Chair Persons: J. Economou, A. Karlsson-Parra

- 368. Engineered immunity for cancer therapy. **J. Economou** (Los Angeles, CA, USA) (30')
- 288. A multi-modality approach in cancer immunotherapy. **A. Karlsson-Parra** (Göteborg, Sweden) (30')
- 252. A novel ibuprofen derivative for the control of breast cancer. **Y. Sun**, L. Huang, B. Rigas (Stony Brook, NY, USA) (30')
- 324. Mesenchymal stem cells as cellular delivery vehicle of soluble TRAIL in human cancer models. **R. Zwacka**, L. Deedigan, J. Courtete, R. Yu, A. Mohr (Galway, Ireland) (30')

EXPERIMENTAL THERAPEUTICS

Room A, 11:30-13:00
Saturday, October 17

Chair Persons: N.C. Popescu, T. Ochi

- 138. Deleted in liver cancer (DLC1) as a metastasis suppressor gene. **N.C. Popescu** (Bethesda, MD, USA) (30')
- 263. Aurora-A kinase: A novel target of cellular immunotherapy for leukemia. **T. Ochi**, H. Fujiwara, M. Yasukawa (Ehime, Japan) (30')
- 171. Targeting of tumors with radiolabeled vitamins. **R. Waibel**, C. Müller, R. Schibli (Villigen, Switzerland) (30')

NITRIC OXIDE/CYTOKINES

Room A, 16:00-17:30
Saturday, October 17

Chair Persons: H.M. Said, S. Rocha

176. Role of chromatin remodeling enzymes in the cellular response to hypoxia. A. Melvin, N. Kenneth, S. Mudie, **S. Rocha** (Dundee, UK) (25')
312. Regulation of hypoxia induced tumor marker genes in human brain tumor cells. **H.M. Said**, C. Hagemann, J. Anacker, G.H. Vince, M. Flentje, D. Vordermark (Wuerzburg; Halle, Germany) (25')
266. Nitric oxide-donating aspirin S-nitrosylates signaling proteins in colon cancer cells: Implications for its mechanism of action. **J.L. Williams**, P. Ji, L. Kopelovich, B. Rigas (Stony Brook, NY; Bethesda, MD, USA) (20')
369. Inhibition of the EMT cascade in metastasis by nitric oxide donors: Novel anti-metastatic drugs. **S. Baritaki**, S. Huerta-Yepez, K. Yeung, K. Wu, D.A. Spandidos, B. Bonavida (Los Angeles, CA; Toledo, OH, USA; Heraklion, Greece) (20')

TUMOR BIOLOGY

Room A, 18:00-19:30
Saturday, October 17

Chair Persons: H.-G. Wang, C.J. Wheeler

209. Autophagy and cancer: BIFFing TGN into autophagosomes. Y. Takahashi, **H.-G. Wang** (Hershey, PA, USA) (30')
254. Changing the inevitable: Age, immunity, genes and malignancy in glioma. D.K. Irvin, E. Jouanneau, G. Duvall, A. Mardiros, A. Panwar, Y. Zhai, X.-X. Zhang, D. Sarayba, A. Seksenyan, K. Black, **C.J. Wheeler** (Los Angeles, CA, USA) (30')
203. Cdc42: A new potential therapeutic target in colorectal cancer. **T. Gómez del Pulgar**, F. Valdés-Mora, E. Bandrés, C. Espina, R. Pérez-Palacios, F.J. Illana, P. Cejas, M.A. García-Cabezas, J. Feliú, M. González-Barón, J. García-Foncillas, J.C. Lacal (Madrid; Pamplona, Spain) (30')

PROSTATE CANCER

Room B, 09:00-11:00
Saturday, October 17

Chair Persons: O. Barbier, P.S. Rennie

124. Pharmacological activators of the Farnesoid X receptor: A new hope for advanced prostate cancer treatment. J. Kaeding, É. Houssin, **O. Barbier** (Québec, Canada) (25')
182. Can targeting the androgen receptor control advanced, hormone-refractory prostate cancer? H. Cheng, R. Snoek, P. Tavassoli, A. Cherkasov, **P.S. Rennie** (Vancouver, Canada) (25')
218. New paradigm for antitumor action of IGF binding protein-3 in prostate cancer. J. Han, S. Jogie-Brahim, **Y. Oh** (Richmond, VA, USA) (25')
221. The Fer tyrosine kinase is at the crossroad of STAT3 and AR signaling in prostate cancer. **S. Chevalier**, J. Cury, F. Zouanat, A. Zoubeidi, E. Scarlata, L. Hamel, A. Aprikian (Montreal, Canada) (25')
152. Epigenetic inactivation of D-glucuronyl C5-epimerase in human prostate cancer: An additional way for abnormal tumour cell glycosylation. T.Y. Prudnikova, N. Soultzis, T. Pavlova, V.I. Kashuba, G.I. Nepomnyashchikh, S.V. Aidagulova, D.A. Spandidos, E.R. Zabarovsky, **E. Grigorieva** (Novosibirsk, Russia; Heraklion, Greece; Stockholm, Sweden) (20')

MOLECULAR BIOLOGY/CLINICAL ONCOLOGY

Room B, 11:30-13:00
Saturday, October 17

Chair Persons: G.P. Stathopoulos, V. Shoshan-Barmatz

375. The mitochondrial protein VDAC as a new target for cancer therapy. **V. Shoshan-Barmatz**, N. Keinan, S. Abu-Hamad, N. Arbel, L. Arzione (Beer-Sheva, Israel) (25')
103. Anti-EGFR molecules in clinical practice (Lapatinib Erlotinib). Safety and effectiveness. **G.P. Stathopoulos**, S.K. Rigatos, J. Koutantos, N. Malamos, J. Stathopoulos (Athens, Greece) (20')
130. Single centre experience with rituximab treatment in non Hodgkin's lymphoma patients. **B. Jezersek Novakovic**, A. Benigar, S. Novakovic (Ljubljana, Slovenia) (25')
131. Combination of CpG ODNs and radiotherapy efficiently delayed growth of subcutaneous B16F1 tumors. **S. Novakovic**, P. Cerkovnik, B. Jezersek Novakovic (Ljubljana, Slovenia) (20')

EXPERIMENTAL THERAPEUTICS/MOLECULAR ONCOLOGY

Room B, 16:00-17:30
Saturday, October 17

Chair Persons: Y.P. Loh, G.E. Voutsinas

237. A carboxypeptidase E isoform controls and predicts metastatic potential of human cancers. **Y.P. Loh**, T. Lee, S.R.K. Murthy, N.X. Cawley, S. Hewitt, I. Ng, R. Poon (Bethesda, MD, USA; Hong Kong, P.R. China) (25')
207. Hsp90 drug targeting in bladder cancer cells. P.K. Karkoulis, D.J. Stravopodis, E.G. Konstantakou, S. Melachroinou, D. Anastasiou, L.H. Margaritis, **G.E. Voutsinas** (Athens, Greece) (15')
389. MicroRNAs: p53 pathway interactions reflect therapeutic response to preoperative chemoradiotherapy in rectal cancer. I. Kocakova, **M. Svoboda**, R. Sefr, J. Smardova, P. Slampa, J. Simicek, J. Garcic, R. Vyzula, T. Long (Brno, Czech Republic) (25')
410. The role of docetaxel chemotherapy re-treatment and other second-line chemotherapy drugs and targeted agents in the management of metastatic castrate resistant prostate cancer. **J. Ansari**, S.A. Hussain, N.D. James, J. Glaholm (Newcastle upon Tyne; Birmingham, UK) (20')

LUNG CANCER/MOLECULAR ONCOLOGY

Room B, 18:00-19:30
Saturday, October 17

Chair Persons: E. Zabarovsky, G.E. Pantelias

155. Novel methylation-dependent markers/tumor suppressor genes involved in the progression of lung, cervical and prostate cancers. T. Pavlova, K. Haraldson, I. Skrypkina, S.P. Yenamandra, V. Senchenko, V. Zabarovska, E. Braga, T. Eschenko, E. Grigorieva, M.I. Lerman, G. Klein, V. Kashuba, **E. Zabarovsky** (Stockholm, Sweden) (25')
238. Checkpoint abrogation in G2-phase irradiated lymphocytes using caffeine: A new approach to predict individual radiosensitivity and genetic predisposition to cancer. **G.J. Terzoudi**, G.E. Pantelias (Athens, Greece) (25')
199. The role of cytogenetic analysis in pediatric acute myeloid leukemia. **K.N. Manola** (Athens, Greece) (20')
128. Metabolic profile of lung cancer cell lines treated with histone deacetylase inhibitor sodium butyrate. N.D. Amoêdo, M.F. Rodrigues, L. Costa, P. Pezzuto, A.L.M. Giannini, R.F.M. Da Costa, M. Benchimol, T. El-Bacha Porto, F.C.L. Almeida, A.G. Filho, **F.D. Rumjanek** (Rio de Janeiro, Brazil) (20')

GYNECOLOGICAL CANCER

Room C, 09:00-11:00
Saturday, October 17

Chair Persons: T. Lanisnik Rizner, A. Chiarini, B.-H. Bay

167. Estrogen-metabolizing enzymes and endometrial cancer. **T. Lanisnik Rizner**, N. Hevir, T. Smuc, J. Sinkovec (Ljubljana, Slovenia) (30')
235. Involvement of protein kinase C- ζ at the nuclear membrane level of VP-16-treated human cervical carcinoma C4-I cells. **A. Chiarini**, M. Marconi, R. Pacchiana, I. Dal Prà, U. Armato (Verona, Italy) (30')
306. The Y-box-binding protein 1 is a marker of tumor proliferation and clinical outcome in breast cancer. Y. Yu, G.W.-C. Yip, P.-H. Tan, **B.-H. Bay** (Singapore) (30')
242. *ING1*, *PTPN2*, *PCID2*, *VGLL1* and *LOC388279* genes as potential prognostic markers in ovarian cancer. **L. Szafron**, K. Lisowska, T. Rubel, P. Sobiczewski, J. Kupryjanczyk (Warsaw; Gliwice, Poland) (15')
304. Stromal adipokines in breast cancer development. **R.A. Woo** (Springfield, IL, USA) (15')

CLINICAL ONCOLOGY/SURGICAL ONCOLOGY

Room C, 11:30-13:10
Saturday, October 17

Chair Persons: L. Vannucci, T. Fujimoto, H.W. Strobel

184. Colonic environment, immunity, cancer: A lesson from germ-free vs. conventionally reared rats. **L. Vannucci**, R. Stepankova, V. Grobarova, M. Kuldova, J. Richter, V. Ullmannova-Benson, P. Vodicka, O. Chernyavskiy, L. Lipska, J. Klepetar, L. Kubinova, P. Rossmann, A. Fiserova (Prague, Czech Republic) (25')
307. Role of para-aortic lymphadenectomy in endometrial cancer. **T. Fujimoto**, H. Nanjyo, Y. Yokoyama, T. Takano, T. Shoji, K. Nakahara, H. Yamada, H. Mizunuma, N. Yaegashi, T. Sugiyama, H. Kurachi, A. Sato, T. Tanaka (Akita; Hirosaki; Sendai; Morioka; Yamagata; Fukushima, Japan) (25')
413. Expression and function of cytochromes p450 4F after traumatic brain injury. **H.W. Strobel**, Y. Wang, J.C. Bell, D.J. Ryder, A. Kalsotra, J. Zhao, P. Dash (Houston, TX, USA) (20')
234. NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery. N. Li, H. Xu, Z.-B. Liu, S. Yang, Q. Song, N. Gu, L.-J. Zhang, J.-L. Lou, **J. Lu** (Beijing, P.R. China) (20')
386. Preventive effects of TCM and TACE on relapse of HCC patient after operation: A retrospective case-control study. **C. Ling**, Z. Chen, H. Chen, Q. Lang, M. Wu (Shanghai, P.R. China) (10')

MICROBIOLOGY

Room C, 16:00-17:30
Saturday, October 17

Chair Persons: G. Chaconas, A. Ilari

253. Vascular interactions of the Lyme disease pathogen in a living host: A role for host GAGs, fibronectin and the *B. burgdorferi* protein BBK32. T.J. Moriarty, M.U. Norman, A.R. Dresser, P. Kubes, **G. Chaconas** (Calgary, Canada) (30')
127. The X-ray structure of trypanothione reductase in complex with NADPH and Sb(III) discloses the molecular basis of antimony treatment in leishmaniasis. P. Baiocco, G. Colotti, S. Franceschini, **A. Ilari** (Rome, Italy) (30')
370. Dynamic recruitment of the RhoB GTPase into HCMV assembly complex in live infected cells. **N. Goulidaki**, D.A. Spandidos, G. Sourvinos (Heraklion, Greece) (15')
371. Block in the progression of mitosis in HCMV primary infected fibroblasts. **P. Dimitropoulou**, N. Goulidaki, D.A. Spandidos, G.W. Wilkinson, G. Sourvinos (Heraklion, Greece; Cardiff, UK) (15')
332. Human papilloma virus (HPV) and recurrent respiratory papillomatosis in childhood: Clinical, histological and molecular characteristics. **I. Mammias**, G. Sourvinos, P. Giamarelou, E. Vakonaki, C. Michael, D.A. Spandidos (Heraklion; Athens, Greece) (15')

MOLECULAR MEDICINE

Room C, 18:00-19:30
Saturday, October 17

Chair Persons: M. Junie, N. Reis

356. Mechanisms of action of the current and new antifungal drugs and their implications in therapy. **M. Junie** (Cluj Napoca, Romania) (25')
357. Comparative diagnostic value of PCR and ELISA methods in the diagnosis of *Echinococcus granulosus* infection. S. Seres, A. Iovu, V. Cozma, **M. Junie** (Cluj Napoca, Romania) (20')
301. Physical and psychological-social problems of cancer patients and their relative in end of life period. **N. Reis** (Erzurum, Turkey) (25')
308. miRNA-mediated osmoregulation in renal cells. **J.Y. Yang**, W. Huang (Xiamen, P.R. China) (20')

MOLECULAR ONCOLOGY/TUMOR BIOLOGY/ANGIOGENESIS

Room D, 09:00-11:00
Saturday, October 17

Chair Persons: A.K. El-Naggar, M.A. Khalifa, C. Stover

392. Autofluorescence screening of oral squamous lesions: Histopathologic basis and confounding factors. **A.K. El-Naggar** (Houston, TX, USA) (25')
181. An update on lymph node assessment for metastatic cancer. **M.A. Khalifa** (Toronto, Canada) (20')
287. Dual role of complement in tumour growth and metastasis. **C. Stover** (Leicester, UK) (20')
134. M-ONC 402 - A non anticoagulant low molecular weight heparin inhibits tumor metastasis in two murine models. H. Zhou, N. Dussault, E. Cochran, R. Kwan, J. Karlgren, M. Barnes, S. Roy, R. Zouaoui, J. Duffner, C.L. Chu, S. Smith, C. Honan, **Z. Galcheva-Gargova**, Y.W. Qi, T. Ganguly, B. Schultes, K. Kishimoto (Cambridge, MA, USA) (20')
215. LOX/COX inhibitors: Possible way to potentiate the antineoplastic effect of retinoids in neuroblastoma and medulloblastoma cell lines. **M. Redova**, P. Chlapek, T. Loja, K. Zitterbart, M. Hermanova, J. Sterba, R. Veselska (Brno, Czech Republic) (20')
216. DNA vaccines against bcr-abl-transformed cells. **V. Lucansky**, E. Sobotkova, R. Tachezy, M. Duskova, K. Babiarova, K. Mocova, J. Mackova, P. Gabriel, J. Suttar, L. Kutinova, M. Smahel, S. Nemeckova, V. Vonka (Prague, Czech Republic) (20')

TUMOR BIOLOGY/MOLECULAR ONCOLOGY

Room D, 11:30-13:00
Saturday, October 17

Chair Persons: R. Veselska, I. Dal Pra

231. Cancer stem cell markers in selected childhood tumors of mesenchymal origin. **R. Veselska**, M. Hermanova, J. Sana, T. Loja, P. Chlapek, I. Zambo, K. Vesely, K. Zitterbart, J. Sterba (Brno, Czech Republic) (25')
230. Angiogenic factor induction in and secretion by cultured phenotypically normal adult human astrocytes (NAHA) exposed to β -amyloid peptides and proinflammatory cytokines. **I. Dal Pra**, A. Chiarini, C. Bonafini, J.F. Whitfield, B. Chakravarthy, U. Armato (Verona, Italy; Ontario, Canada) (25')
107. Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high stage gastric cancer. **X.-T. Hu**, F.-B. Zhang, W.-F. Lao, Y.-C. Fan, X.-S. Shu, A.H.Y. Wong, Q.-L. Shi, H.-M. Tang, L. Fu, X.-Y. Guan, Q. Tao, C. He (Zhejiang; Hong Kong, P.R. China) (20')
118. Canonical and noncanonical Wnt pathway: A comparison among normal ovary, benign ovarian tumor and ovarian cancer. **L. Badiglian Filho**, C.T.F. Oshima, F. De Oliveira Lima, H. De Oliveira Costa, R. De Sousa Damião, T.S. Gomes, W.J. Gonçalves (São Paulo, Brazil) (20')

CANCER CHEMOPREVENTION AND THERAPY

Room D, 16:00-17:30
Saturday, October 17

Chair Persons: E.M.V. Reiche, J. Prados

257. Association of tumor necrosis factor beta (TNF- β) genetic polymorphism and sepsis susceptibility in Brazilian population. F. Delongui, **E.M.V. Reiche**, M.A.E. Watanabe, C.M.C. Grion, H.K. Morimoto, A.M. Bonametti, J.M.M. Oda, T. Matsuo (Londrina, Brazil) (25')
112. The cytotoxic activity of the phage E protein suppress the growth of murine B16 melanomas *in vitro* and *in vivo*. R. Ortiz, **J. Prados**, C. Melguizo, A.R. Rama, A. Segura, F. Rodríguez-Serrano, H. Boulaiz, F. Hita, A. Martinez-Amat, R. Madeddu, J.L. Ramos, A. Aranega (Granada; Jaén, Spain; Sassary, Italy) (25')
111. Anti-tumor activity of Tanshinone II A and 5-FU in human colon cancer colo 205 xenograft model. **C.-C. Su**, Y.-H. Lin, F.-Y. Pan, C.-Y. Hsiao (Hualien, Taiwan, R.O.C.) (20')
188. Clinical experience of glycosylated somatostatin¹⁴. M. Márquez, S. Nilsson, J. Cortes, **A.R. Holmberg** (Stockholm, Sweden; Monterrey, Mexico) (20')

ALTERNATIVE MEDICINE AND CANCER PREVENTION

Room D, 18:00-19:30
Saturday, October 17

Chair Persons: T.-Y. Lee, O. Froy

290. Molecular mechanisms of herbal medicine Yin-Chen-Hao-Tang on hepatic peroxisome proliferators activated receptor gamma in obese mice. **T.-Y. Lee**, H.-H. Chang, H.-C. Lin (Taoyuan; Taipei, Taiwan, R.O.C.) (25')
115. Effect of feeding regimens on circadian rhythms. **O. Froy**, N. Chapnik, R. Miskin (Rehovot, Israel) (25')
114. Anticancer effects of anthocyanins isolated from *Vitis coignetiae* Pulliat (Meoru in Korea). **W.S. Lee**, D.Y. Shin, M.J. Kim, J.W. Yun, I. Tsoy, H.J. Kim, S.J. Lee, C.H. Ryu, S.C. Shin, Y.H. Choi (Jinju; Busan, South Korea) (20')
191. The mouse urinary bladder carcinogenesis model as a paradigm for urothelial oncogenesis and chemoprevention. **P.A. Oliveira** (Vila Real, Portugal) (20')

POSTERS

110. Transarterial chemoembolization as a salvage therapy unsuccessful hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. **K. Fukumori**, Y. Yano, E. Ando, S. Sumie, K. Kuwaki, F. Yamashita, M. Tanaka, M. Sata (Fukuoka; Saga, Japan)
125. Measures of unconjugated and conjugated steroids using highly sensitive and specific mass spectrometry-based assays. R. Bérubé, S. Caron, **O. Barbier**, C. Guillemette (Quebec, Canada)
126. Agonists of the Farnesoid X-receptor inhibit the expression and signalling activity of the androgen receptor in prostate cancer cells. J. Kaeding, É. Houssin, **M. Verreault**, O. Barbier (Québec, Canada)
129. c-Myb prevents apoptosis of colon carcinoma cells in Cox-2-independent manner. **L. Knopfova**, K. Nesporova, P. Benes, J. Smarda (Brno, Czech Republic)
135. MUC1 and carbohydrate antigenic expression in breast benign disease and normal mammary gland. S.O. Demichelis, C.G. Alberdi, W.J. Servi, M.T. Isla-Larrain, A. Barbera, F. Terrier, A. Cretón, A. Segal-Eiras, **M.V. Croce** (La Plata, Argentina)
141. BRAF wildtype in salivary gland carcinomas - Implications for anti-EGFR therapies. **R. Dahse**, K. Kromeyer-Hauschild, A. Berndt, H. Kosmehl (Erfurt; Jena, Germany)
143. Clinicopathological correlations of cyclooxygenase-2, MDM2, and p53 expression in surgically resectable pancreatic invasive cancer. **M. Hermanova**, P. Karasek, R. Nenutil, J. Tomasek (Brno, Czech Republic)
145. The role of p53 in SV40 associated B-cell lymphoma. **S. Heinsohn**, R. Scholz, H. Kabisch (Hamburg, Germany)
148. Establishment of combined immuno-chemotherapy with systemically administered gemcitabine and intra-portal administration of interleukin-2 in murine models of liver metastases of pancreatic cancer. **Y. Ito**, K. Aiura, M. Ueda, M. Kitajima, Y. Kitagawa (Tokyo; Kanagawa, Japan)
157. Combination of Plk1 inhibitors with anti-neoplastic agents. **S. Keppner**, E. Proschak, I. Steinhauser, K. Langer, K. Strebhardt, G. Schneider, B. Spänkuch (Frankfurt; Münster, Germany)
159. Aberrant expression of human ortholog of mammalian enabled (hMena) in human colorectal carcinomas. **A. Toyoda**, H. Kawana, K. Azuhata, J. Yu, A. Yokota-Omata, H. Kishi, M. Higashi, M. Kitagawa, K. Harigaya (Chiba, Japan)
162. ILK expression in human basal cell carcinoma correlates with EMT markers and tumor invasion. S. Papanikolaou, **V. Bravou**, K. Gyftopoulos, D. Nakas, M. Repanti, H. Papadaki (Patras, Greece)
165. Pulmonary metastasectomy for uterine cervical cancer: A multivariate analysis. **K. Yamamoto** (Osaka, Japan)
177. The use of external prostheses in the breast reconstruction as an alternative to surgical reconstruction. **D.M. Trevisani**, H.M. Tanimoto, M.Z. Macari, K.S.M. Macari, A.L. De Oliveira Avi, A.G.Z. Matthes (São Paulo, Brazil)
192. The effect of gemcitabine on urothelial lesions induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in ICR male mice. C. Vasconcelos-Nóbrega, A. Colaço, L. Santos, H. Vala, L.F. Palomino, C. Lopes, **P.A. Oliveira** (Viseu; Vila Real; Porto, Portugal; Lugo, Spain)
200. Chromosome abnormalities, clinical features and outcome in a large series of pediatric patients with acute myeloid leukemia in Greece. **K. Manola**, A. Parcharidou, E. Hatzipantelis, M. Pagoni, V. Papadakis, A. Vourtsi, F. Tzortzatos-Stathopoulou, M. Baka, M. Kalmanti, G. Pantelias, C. Sambani, S. Polychronopoulou (Athens; Thessaloniki; Crete, Greece)
204. Growth inhibitory effects of pegylated IFN- α 2b and 5-fluorouracil in combination on renal cell carcinoma cell lines *in vitro* and *in vivo*. **F. Moriya**, S. Ogasawara, Y. Basaki, J. Akiba, S. Kojiro, S. Fukahori, H. Ishizaki, N. Nishida, K. Matsuoka, M. Kojiro, M. Kuwano, H. Yano (Fukuoka, Japan)
205. Immunohistochemical expression of Ezrin and CD44H in a series of children and adolescents with osteosarcoma. **E. Boldrini**, S. Peres, L. Feltrin, S. Morini, B. De Camargo (São Paulo, Brazil)
212. The effects of 17 β -estradiol on the proliferation, invasion and metastasis genes expression of cholangiocarcinoma cells *in vitro*. **P. Thuwajit**, C. Thuwajit (Bangkok; Khon Kaen, Thailand)

223. Anti-tumoral mechanisms of *Bacillus licheniformis* through the control of reactive tumor stroma. **J.K. Park**, C.-S. Yang, K.-H. Kim, H.-H. Choi, M.-S. Lim, E.-K. Jo, H.-J. Kim (Daejeon, Korea)
226. The O-linked N-acetylglucosamine modification and Akt signaling pathway in thyroid cancer cells. **A. Krzeslak**, A. Lipinska (Lodz, Poland)
232. Copy number changes of *MYCC* and *MYCN* genes detected by I-FISH are useful prognostic markers in children with medulloblastoma: A study from the University Hospital Brno. K. Zitterbart, D. Kantorova, H. Filkova, D. Zezulkova, E. Necesalova, I. Slamova, V. Vranova, L. Tomasikova, M. Pesakova, A. Oltova, Z. Pavelka, J. Sterba, P. Kuglik, **R. Veselska** (Brno, Czech Republic)
239. The radiosensitizing potential of glutaraldehyde on MCF7 breast cancer cells using the G2-chromosomal radiosensitivity assay. V.I. Hatzl, **G.I. Terzoudi**, K. Barszczewska, V. Makropoulos, G.E. Pantelias (Athens, Greece)
241. Clusterin/XIP8 is a stress inducible protein in Hodgkin lymphoma cell lines. **R. Frazzi**, B. Casali, M. Iori, M. Paiusco, F. Merli (Reggio Emilia, Italy)
245. The prevalence of aminoglycoside resistance and corresponding resistance genes in clinical isolates of staphylococci from two hospital cancer centers in Brazil and the USA. **D.M. Trevisani**, M. Syvanen, H.M. Tanimoto, J. Knowles, A.S. Ferraudo (São Paulo, Brazil; Davis, CA, USA)
246. Evaluation of the surgeon-dentists' knowledge about oral cancer in Barretos Region-São Paulo, Brazil. **D.M. Trevisani**, A.L.R. De Oliveira Avi, H.M. Tanimoto, S.H.K. Rios, J.G. Junior, C.D. Queiroz, E.M. De Lima, J.F. Maruco, A.L. Carvalho (São Paulo, Brazil)
248. Analysis of gene silencing mechanisms in laryngeal squamous cell carcinoma. **J. Colombo**, M. De Freitas Calmon, S.R. Valentini, P. Peitl Jr, P. Rahal (São José do Rio Preto; São Paulo, Brazil)
249. The impact of 131I-mIBG rescue therapy in the survival of a patient with ganglioneuroblastoma. A.T.T. Parra, **S.M. Moriguchi**, M.C.P. Gonçalves, M.A.M.F.F. Esteves, M.J. Santos, L.M. Gracioli, E. Boldrini, E.T. Rocha (São Paulo, Brazil)
250. Breast hemangioma investigation - Case report. S.S. Ferreira, **S.M. Moriguchi**, M.C.P. Gonçalves, A. Alexandrino, C.N. Galvão, R.A.C. Vieira, E.T. Rocha (São Paulo, Brazil)
259. Senescence-induced p53 reduction is achieved by progerin, alternative splicing product of lamin A and causal gene of Hutchinson Gilford progeria syndrome. **S.J. Lee**, S.H. Lee, J.Y. Chung, Y.S. Jung, N.C. Ha, B.J. Park (Busan, Korea)
267. The target of cysteinyl-leukotriene₁ receptor (CysLT₁R) is new anti-cancer strategy for human prostate cancer. **M. Matsuyama**, K. Funao, T. Naganuma, K. Kuratsukuri, T. Tanaka, Y. Takemoto, T. Nakatani, R. Yoshimura (Osaka, Japan)
268. Over-expression of cysteinyl-leukotriene₁ receptor in human renal cell carcinoma and its antagonist inhibits renal cell carcinoma cell growth through apoptosis. **K. Funao**, M. Matsuyama, T. Hayama, K. Kuratsukuri, T. Tanaka, Y. Takemoto, T. Nakatani, R. Yoshimura (Osaka, Japan)
272. A pilot study of vasculogenic mimicry immunohistochemical expression in intraocular melanoma model. **B. Sun**, L. Chen (Tianjin, P.R. China)
276. Detection of metallothionein and alpha-methylacyl CoA racemase as potential new markers for prostate carcinoma. **M. Masarik**, J. Gumulec, S. Kuchticková, V. Adam, S. Krížková, R. Kizek (Brno, Czech Republic)
277. Doxorubicin and genomic DNA, new insights in drug-nucleic acids interactions. **M. Masarik**, D. Húska, V. Adam, J.V. Burda, T. Eckschláger, M. Stiborová, R. Kizek (Brno; Prague, Czech Republic)
278. Metallomics of melanoma animal tissues. **M. Masarik**, O. Zítka, D. Húska, S. Krížková, J. Strnadel, V. Horák, T. Vaculovic, K. Novotny, V. Kanicky, J. Kaiser, V. Adam, R. Kizek (Brno, Czech Republic)
279. Relationship of metalloproteinases with metallothioneins. **M. Masarik**, O. Zítka, D. Húska, S. Krížková, V. Adam, J. Kukacka, R. Prusa, V. Zízková, R. Kizek (Brno; Prague, Czech Republic)
283. Gleevec reduction of TRAIL-induced apoptosis in colon cancer cells: Death receptor activated c-Abl leading to stress kinase-dependent cell death. M.-H. Tai, D.-Y. Huang, **W.-W. Lin** (Taipei, Taiwan, R.O.C.)

285. Increased expression of cystatin C and transforming growth factor β -1 in calcific aortic valves. **E. Yetkin**, V. Tchaikovski, N. Erdil, S. Alan, J. Waltenberger (Maastricht, The Netherlands; Malatya, Turkey)
289. AF-16, a peptide derived from the endogenous protein antiseecretory factor, decreases tumor interstitial fluid pressure. **A.C. Wallgren**, M. Al-Olama, H.-A. Hansson, B. Andersson, S. Lange, A. Karlsson-Parra, E. Jennische (Göteborg, Sweden)
293. 15-deoxy- $\Delta^{12,14}$ -prostaglandin J_2 up-regulates death receptor 5 gene expression in colon cancer cells: Involvement of reactive oxygen species and C/EBP homologous transcription factor gene transcription. **D.-Y. Huang**, R.-Y. Su, M.-H. Tai, W.-W. Lin (Taipei, Taiwan, R.O.C.)
297. RNA-binding proteins involved in nerve cell differentiation. C.M. Di Liegro, P. Proia, G. Schiera, A. Lo Cicero, G. Accard, **I. Di Liegro** (Palermo, Italy)
298. Proapoptotic effects of oligodendroglioma cells on primary brain cells in culture. A. Lo Cicero, G. Schiera, P. Proia, D. Cinaru, **I. Di Liegro** (Palermo, Italy)
299. Effect of sera from patients with multiple sclerosis on a blood-brain barrier *in vitro* model. P. Proia, G. Schiera, A. Lo Cicero, G. Salemi, P. Ragonese, G. Savettieri, **I. Di Liegro** (Palermo, Italy)
302. Isolation and analysis of tumor microvesicles from serum samples of cancer patients. M.E. Rabassa, A. Segal-Eiras, **M.V. Croce** (La Plata, Argentina)
303. Roles of L-type calcium channels in aspirin exacerbation of IgE-dependent mast cell activation. **M. Murai**, Y. Suzuki, K. Togo, T. Inoue, M. Suzuki-Karasaki, T. Ochiai, C. Ra (Tokyo, Japan)
309. DNA damage sensor protein hRad9 - A novel molecular target for lung cancer treatment. **Y. Maniwa** (Kobe, Japan)
313. Expression of the epidermal growth factor (EGF-R) and the tumor suppressor PTEN in human malignant gliomas. **S. Horn**, A. Schollmayer, M. Buckan, W. Brenner, J. Conrad, W. Wagner (Mainz, Germany)
314. Aggressive tumor in differentiated thyroid carcinoma conducted by the nuclear medicine. D.S. Cunha, **S.M. Moriguchi**, M.I.P. Simões, D.N. Viviani, D. Boldini, E.T. Rocha (São Paulo, Brazil)
315. Chondroblastic osteosarcoma of mandible: Case report. D.N. Viviani, **S.M. Moriguchi**, R.R. Barra, M.J. Santos, E.T. Rocha (São Paulo, Brazil)
316. Melorheostosis - Rare condition evaluated by nuclear medicine. Case report and literature review. R.R. Barra, **S.M. Moriguchi**, D.N. Viviani, D.S. Cunha, E.T. Rocha (São Paulo, Brazil)
317. Scintigraphy finding of ureteral fistula conduct indicates therapy - Case report and literature review. R.R. Barra, **S.M. Moriguchi**, D.N. Viviani, M.C.P. Gonçalves, E.T. Rocha (São Paulo, Brazil)
318. Metastatic cervical paraganglioma: Rare case conducted by the nuclear medicine successfully. Case report and literature review. A. Alexandrino, **S.M. Moriguchi**, R.R. Barra, M.J. Santos, E.T. Rocha (São Paulo, Brazil)
319. Giant cell tumor, a difficulty of pathologist that can be clarified by nuclear medicine: Case report. M.A.M.F.F. Esteves, **S.M. Moriguchi**, P.F.K. Faria, R.R. Barra, M.J. Santos, E.T. Rocha, M.C.P. Gonçalves (São Paulo, Brazil)
320. Primary breast lymphoma. Rare neoplasm documented by nuclear medicine - Case report. P.F.K. Faria, **S.M. Moriguchi**, M.A.M.F.F. Esteves, R.R. Barra, M.J. Santos, E.T. Rocha, M.C.P. Gonçalves (São Paulo, Brazil)
321. Physiotherapeutic stimulation: Lymphoedema prevention in axillary lymph node dissection of breast cancer. A.J. Sarri, **S.M. Moriguchi**, S.V. Peres, E.T. Silva, K.H. Koga, A.G.Z. Mathes, R.L. Haikek, M.J. Santos, E.T. Rocha, R. Dias (São Paulo, Brazil)
330. Sp1 activates expression of TAp73 γ isoform in lung cancer. **S. Logotheti**, I. Michalopoulos, D.A. Spandidos, T. Liloglou, V. Zoumpourlis (Athens; Heraklion, Greece; Liverpool, UK)
333. Second-generation prophylactic vaccines against human papilloma virus (HPV): An update. **F. Maher**, C. Weigert, I. Mamas, G. Sourvinos, D.A. Spandidos (Liverpool, UK; Regensburg, Germany; Heraklion, Greece)

334. Vaccinating children against human papilloma virus (HPV) in the developing world: A new challenge. **F. Maher**, C. Weigert, I. Mammias, G. Sourvinos, D.A. Spandidos (Liverpool, UK; Regensburg, Germany; Heraklion, Greece)
335. Comparison of different molecular methodologies for the detection of human papilloma virus (HPV). **A. Zaravinos**, I. Mammias, E. Vakonaki, A. Zafiroopoulos, G. Sourvinos, D.A. Spandidos (Heraklion, Greece)
336. Down-regulation of nuclear *PAWR* expression in primary breast cancer is correlated with poor prognosis. **M.A. Nagai**, S.A. De Bessa-Garcia, S. Salaorni, J.H. Fregnani, S. Nonogaki, M.M. Netto, F.A. Soares (São Paulo, Brazil)
342. Set up of a NK cell-sensitive tumour model in C57BL/6 mice. **R. Gambari**, A. Capezzone de Joannon, B. Garrone, P. Giacomini, E. Tremante, E. Lo Monaco, G. Breveglieri, N. D'Atanasio, A. Amato, C. Milanese (Ferrara; Rome, Italy)
343. Expression of miR-210 during erythroid differentiation and induction of γ -globin gene expression. N. Bianchi, C. Zuccato, I. Lampronti, M. Borgatti, **R. Gambari** (Ferrara, Italy)
344. Virtual screening of a furocoumarin database against NF- κ B: Identification of anti-inflammatory molecules for cystic fibrosis. L. Piccagli, E. Fabbri, M. Borgatti, N. Bianchi, V. Bezzetti, I. Mancini, N. Mori, E. Nicolis, M.C. Dececchi, A. Tamanini, I. Lampronti, F. Dall'Acqua, D. Vivaldi, G. Cabrini, **R. Gambari** (Ferrara; Verona; Padova, Italy)
345. Release of sICAM-1 and HLA-G molecules in human oocytes and *in vitro* fertilized human embryos. M. Borgatti, R. Rizzo, M.B. Dal Canto, D. Fumagalli, M. Mignini Renzini, R. Fadini, M. Stignani, O.R. Baricordi, **R. Gambari** (Ferrara; Monza, Italy)
346. TNF-alpha induced release of IL-8 by IB3-1 cells encapsulated in alginate microbeads. M. Borgatti, S. Mazzitelli, G. Breveglieri, V. Costa, **R. Gambari**, C. Nastruzzi (Ferrara; Perugia, Italy)
347. Production of β -globin and adult hemoglobin following G418 treatment of erythroid precursor cells from homozygous $\beta^0/39$ thalassemia patients. F. Salvatori, G. Breveglieri, Z. Zuccato, A. Finotti, N. Bianchi, M. Borgatti, G. Feriotto, F. Destro, A. Canella, E. Brognara, I. Lampronti, L. Breda, S. Rivella, **R. Gambari** (Ferrara, Italy; New York, NY, USA)
348. EBV markedly influences the pathogenesis of nasal polyps. **A. Zaravinos**, J. Bizakis, D.A. Spandidos (Heraklion, Greece)
349. Viral infection and H-RAS activation appear to represent independent factors in the etiology of actinic keratosis and non-melanoma skin cancers. **A. Zaravinos**, P. Kanellou, D.A. Spandidos (Heraklion, Greece)
350. RAF and RKIP implication in urinary bladder cancer. **M. Chatziioannou**, A. Zaravinos, I. Boulalas, D.A. Spandidos (Heraklion; Athens, Greece)
355. The significance of *CYP11A1* polymorphism in endometrial and ovarian cancers in the Polish population. A. Seremak-Mrozikiewicz, P.M. Mrozikiewicz, **A. Semczuk**, T. Rechberger, K. Drews (Poznan; Lublin, Poland; Berlin, Germany)
358. Prevalence of *Echinococcus granulosus* in Cluj county, Romania. S. Seres, A. Iovu, V. Cozma, **M. Junie** (Cluj Napoca, Romania)
362. Polymorphisms of fractalkine receptor *CX3CR1* gene in patients with symptomatic and asymptomatic carotid artery stenosis. **M. Kimouli**, S. Miyakis, P. Georgakopoulos, A.D. Achimastos, E.N. Neofytou, D.A. Spandidos (Heraklion; Athens, Greece)
363. The effect of an exon 12 polymorphism of the human thromboxane synthase (*CYP5A1*) gene in stroke patients. **M. Kimouli**, V. Gourvas, X. Konstantoudaki, M. Basta, S. Miyakis, D.A. Spandidos (Heraklion; Athens, Greece)
366. Coregulation of dipeptidyl peptidase-IV and fibroblast activation protein in glioma cell lines. **E. Balaziová**, L. Kotackova, A. Sedo (Prague, Czech Republic)
372. Plasma cell-free fetal DNA exhibits significantly higher concentration in early than late preeclampsia and control pregnancies. **A. Zaravinos**, S. Sifakis, N. Maiz, D.A. Spandidos, K.H. Nicolaides (London, UK; Heraklion, Greece)
374. Cosmetic textiles with biological benefits. S.Y. Cheng, M.C.W. Yuen, C.W. Kan, K.K.L. Cheuk, K.H. Lam, **C.H. Chui**, R. Gambari (Hong Kong, P.R. China; Ferrara, Italy)
377. Endometrial adenocarcinoma as mitochondrial disorder. **A. Semczuk**, A.M. Czarnecka, A. Klemba, K. Plak, B. Kofler, P. Golik, E. Bartnik (Lublin; Warsaw, Poland; Salzburg, Austria)

378. *APC* promoter hypermethylation is an early event in endometrial tumorigenesis. A. Ignatov, J. Bischoff, C. Schwarzenau, T. Krebs, T. Beni, D. Kuester, K. Herrmann, S.D. Costa, A. Roessner, **A. Semczuk**, R. Schneider-Stock (Magdeburg, Germany; Lublin, Poland)
380. Phenotypic mismatch DNA repair *hMSH2* and *hMLH1* gene expression profile: A potential diagnostic histological staging and prognostic survival marker in lung carcinomas. **D. Vageli**, Z. Daniil, J. Dahabreh, K. Gourgoulialis, G.K. Koukoulis (Larissa; Athens, Greece)
381. *MSH2* and *MLH1* phenotypic profiles of two rare cases of synchronous histomorphologically distinct gastric adenocarcinomas with gastrointestinal stromal tumors of the proximal small bowel: Informative, 'all purpose', practical tumor markers. **D. Vageli**, E. Athanassiou, G.K. Koukoulis (Larissa, Greece)
382. Investigation of herpes simplex virus type 1 (HSV-1), human herpesvirus 6 (HHV-6) and cytomegalovirus in lung tissue biopsy and bronchoalveolar lavage fluid (BALF) of patients with fibrotic idiopathic interstitial pneumonias (f-IIPs). I. Lasithiotaki, **K.M. Antoniou**, R. Lymbouridou, E.K. Symvoulakis, E. Lagoudaki, D.A. Spandidos, N.M. Sifakas, G. Sourvinos (Heraklion, Crete)
387. CD155/Necl-5 immunolocalization in melanocytic skin lesions. F. D'Amico, A. Amoroso, **E. Skarmoutsou**, M. Consolo, Y. Bevelacqua, F. Stivala, M.C. Mazzarino, G. Malaponte (Catania, Italy)
397. Tumor apoptosis by indole-3-acetic acid/light in B16F10 melanoma-implanted nude mice. S.-Y. Kim, M.-K. Kim, S.-B. Kwon, J.-I. Na, K.-C. Park, **D.-S. Kim** (Seoul, Korea; Stockton, CA, USA)
398. The regulatory mechanism of melanogenesis by FTY720, a sphingolipid analogue. J.E. Lee, S.Y. Kim, Y.-M. Jeong, H.-Y. Yun, K.J. Baek, N.S. Kwon, M.-K. Kim, K.-C. Park, **D.-S. Kim** (Seoul, Korea; Stockton, CA, USA)
399. Sphingosine-1-phosphate decreases melanin synthesis via MITF phosphorylation through the S1P₃ receptor subtype. **D.-S. Kim**, S.-H. Park, Y.-M. Jeong, S.-B. Kwon, A.J. Miller, D.E. Fisher, M.-K. Kim, K.-C. Park (Seoul, Korea; Charlestown, MA; Stockton, CA, USA)
400. Experimental photodynamic therapy for liver cancer cell-implanted nude mice by an indole-3-acetic acid and intense pulsed light combination. K.-C. Park, S.-Y. Kim, M.-K. Kim, **D.-S. Kim** (Seoul, Korea; Stockton, CA, USA)
401. Absence of human papillomavirus infection in normal and malignant bladder. **G. Panagiotakis**, D. Papadogianni, N. Soultziz, G. Sourvinos, D.A. Spandidos (Heraklion, Greece)
402. High prevalence of human herpesviruses in urothelial carcinomas. **G. Panagiotakis**, D. Papadogianni, N. Soultziz, G. Sourvinos, D.A. Spandidos (Heraklion, Greece)
404. Reduced expression of annexin V in placentas of pregnancies with preeclampsia. V. Gourvas, **E. Dalpa**, N. Soultziz, O. Koukoura, P. Fragiadaki, A. Konstantinidou, S. Sifakis, D.A. Spandidos (Heraklion; Athens, Greece)
405. mRNA expression of hypoxia factors HIF-1a, HIF-2a, HIF-b and PHD-3 in pregnancies affected by fetal growth restriction. **V. Gourvas**, S. Sifakis, E. Dalpa, N. Soultziz, D. Koutroulakis, O. Koukoura, A. Konstantinidou, D.A. Spandidos (Heraklion; Athens, Greece)
406. mRNA expression of Δ Np63 and Δ Np73 isoforms in urothelial malignancies. **D. Papadogianni**, N. Soultziz, D.A. Spandidos (Heraklion, Greece)
407. The role of p53 gene family in bladder cancer. **D. Papadogianni**, N. Soultziz, D.A. Spandidos (Heraklion, Greece)
411. Mutation and expression analysis of B-Raf oncogene in benign and malignant tumors of the thyroid gland. **S.P. Derdas**, V. Balis, N. Soultziz, G.H. Sakorafas, D.A. Spandidos (Heraklion; Athens, Greece)
412. Mutation and expression analysis of the Ras family oncogenes in benign and malignant tumors of the thyroid gland. **S.P. Derdas**, V. Balis, N. Soultziz, G.H. Sakorafas, D.A. Spandidos (Heraklion; Athens, Greece)